Opinion|Videos|February 3, 2025
Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis
Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
- Discuss the treatment options with strong recommendations and high certainty of evidence.
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Cyclosporiasis in 2026: A clinical update for pediatricians
2
Joyce Woo, MD, on how hospital factors may influence cardiac transfer timing for newborns
3
Supporting the language development of deaf and hard of hearing children: A clinical guide for pediatric providers
4
Pertussis resurgence: An expert Q&A on diagnostic delays and point-of-care testing
5